Evidence map›Paper›PMID 29247513›Full record

Trial reportClinical cardiology2017

Clinical efficacy of irrigated catheter application of amiodarone during ablation of persistent atrial fibrillation.

Xingfu Huang, Yanjia Chen, Yuli Huang, Hongxin Zhao, Yanyu Chen, Liwei He, Shenrong Liu, Vikram Shee, Dingli Xu, Jian Peng

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. [Amiodarone promotes heat-induced apoptosis, inflammation and oxidative stress in mouse HL1 atrial myocytes].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xingfu HuangDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0001-6823-4602
Yanjia ChenDepartment of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yuli HuangDepartment of Cardiology, The First People's Hospital of Shunde, Foshan, China.
Hongxin ZhaoShanghai Roche Pharmaceuticals Ltd., Shanghai, China.ORCID http://orcid.org/0000-0001-7906-2797
Yanyu ChenDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liwei HeDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shenrong LiuDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Vikram SheeDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Dingli XuDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jian PengDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPharmacological treatment during ablation of persistent atrial fibrillation (AF) is common, but utility of irrigated catheter application of amiodarone during ablation of persistent AF remains unclear. HYPOTHESIS: Irrigated catheter application of amiodarone improves quality of ablation and long-term outcomes.

methodsWe enrolled 90 persistent AF patients who underwent catheter ablation. Patients were randomized to the amiodarone group (n = 45) or control group (n = 45). All patients underwent stepwise ablation beginning with isolation of the pulmonary veins. Next, we performed ablation of linear lesions and focal triggers until sinus rhythm (SR) was achieved. The primary endpoint was documented atrial arrhythmia during follow-up. The secondary endpoint was cardioversion to SR during ablation.

resultsAll pulmonary veins were successfully isolated. Conversion of AF to SR occurred more frequently in the amiodarone group than in the control group (33 vs 23 [73.3% vs 51.1%]; P = 0.03). The amiodarone group had lower procedure, radiofrequency, and fluoroscopy times than the control group (167.4 ± 22.5 min vs 186.7 ± 25.3 min; 78.3 ± 14.2 min vs 90.4 ± 15.5 min; and 6.5 ± 1.9 min vs 8.6 ± 2.4 min, respectively; P < 0.05). More importantly, the atrial arrhythmia recurrence-free survival rates were 80% in the amiodarone group and 60% in the control group during the 14.7 ± 7.5-month follow-up (P = 0.043).

conclusionsIrrigated catheter application of amiodarone during ablation for persistent AF resulted in higher cardioversion rates and lower procedure times and significantly reduced rates of atrial arrhythmia recurrence.

Indexed as

CathetersAmiodaroneAnti-Arrhythmia AgentsAtrial FibrillationCatheter AblationElectrocardiographyEquipment DesignFemaleFluoroscopyHeart Conduction SystemHumansInfusions, IntravenousMaleMiddle AgedSurgery, Computer-AssistedTelemetryAmiodaroneAnti-Arrhythmia AgentsAmiodaroneAtrial ArrhythmiaAtrial fibrillationCatheter AblationHigh-Resolution Mapping

Identifiers

PMID29247513
PMCPMC6490422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.